Menopause Education Series
A Deeper Dive into Estrogen
Estrogen is the most effective treatment for menopausal symptoms, and the most misunderstood. This guide covers the biology, the different formulations, why the route of delivery changes everything, and what the safety data actually show.
Estrogen Biology: What You Need to Know
Understanding the basics helps you understand why formulation, route, and timing all matter.
Oral vs Transdermal: Why the Route Changes Everything
This is the single most actionable piece of information in menopause medicine. The same hormone, delivered differently, has a fundamentally different risk profile.
| Metric | Oral Estrogen | Transdermal Estradiol (Patch/Gel/Spray) |
|---|---|---|
| First-pass liver metabolism | Yes: liver sees 4-5x peripheral levels | No: bypasses liver entirely |
| VTE (blood clot) risk | Increased ~2-fold | NOT increased |
| Stroke risk | Increased at standard dose | NOT increased |
| Triglycerides | Increased 15-25% | Neutral or decreased |
| SHBG | Increased significantly | Minimal change |
| CRP (inflammation) | Increased | Neutral or decreased |
| Clotting factors | Increased | No significant change |
| Gallbladder disease | Increased ~1.5-2x | Minimal effect |
| VMS efficacy | Effective | Equally effective |
| Bone protection | Yes | Yes |
| Bioidentical available | Yes (oral estradiol) | Yes (estradiol patches/gels) |
What the guidelines say
NAMS (2022): “Transdermal estradiol is preferred for women at increased VTE risk.”
IMS (2016): “Transdermal estradiol is associated with less risk of VTE and stroke.”
British Menopause Society: Transdermal recommended as first-line, especially for BMI >30, migraine with aura, or VTE risk factors.
Why this matters for interpreting the WHI
The WHI used oral conjugated equine estrogens, not transdermal estradiol. Many of the risks identified in WHI (VTE, stroke, possibly coronary events) may be partly or wholly attributable to the oral route. Transdermal estradiol was never tested in the WHI.
Estrogen Formulations Compared
Not all estrogen is the same. Here are the major formulations, what makes them different, and when each one makes sense.
Transdermal Estradiol: Patches
Climara, Vivelle-Dot, Menostar
17β-estradiol delivered through the skin via a patch. Changed once or twice weekly depending on the product. Available in doses from 0.014 mg/day (ultra-low) to 0.1 mg/day. Bypasses the liver, achieving a physiologic estradiol-to-estrone ratio similar to premenopausal levels.
Transdermal Estradiol: Gels & Sprays
EstroGel, Divigel, Evamist
Same bioidentical 17β-estradiol as patches, applied daily as a gel to the arm or thigh, or as a metered spray to the forearm. Same liver-bypassing benefits as patches.
Oral 17β-Estradiol
Estrace, generic micronized estradiol
Bioidentical micronized estradiol taken by mouth. While it uses the same molecule as transdermal products, oral delivery means it undergoes first-pass liver metabolism, converting much of the estradiol to estrone (the weaker estrogen) and stimulating hepatic protein synthesis.
Conjugated Equine Estrogens (CEE)
Premarin
Derived from pregnant mare urine. Contains a complex mixture of at least 10 estrogenic compounds including equine estrogens (equilin, 17α-dihydroequilin) that are not found in humans. This was the formulation tested in the WHI. While effective and extensively studied, it is neither bioidentical nor transdermal.
Vaginal Estrogen (Local)
Vagifem/Yuvafem, Imvexxy, Estring, Estrace cream
Low-dose estrogen applied directly to vaginal tissue. Available as tablets, inserts, creams, and rings. Minimal systemic absorption means serum estradiol generally stays below 20 pg/mL. Specifically treats genitourinary syndrome of menopause. It does NOT treat hot flashes or provide bone protection at low doses.
Starting doses
Current guidelines recommend starting at the lowest effective dose and titrating up. Typical starting doses: Transdermal patch: 0.025-0.05 mg/day. Transdermal gel: 0.75 mg/day. Oral estradiol: 0.5-1 mg/day. Improvement typically begins within 2-4 weeks, with full effect by 8-12 weeks.
Estrogen Safety: What the Evidence Actually Shows
The safety profile of estrogen depends on the route, the formulation, the timing, and whether a progestogen is used. Blanket statements about “estrogen risk” are misleading.
The safest systemic estrogen regimen:
- Transdermal estradiol : avoids hepatic first-pass, so no VTE, no stroke risk, no triglyceride increase
- + micronized progesterone if uterus is intact : better breast safety profile than MPA, sleep benefit
- + initiated within 10 years of menopause
- + lowest effective dose
- + annual reassessment
This addresses every modifiable risk factor identified in the research.